HWEE-YONG YAP, M.D.; GEORGE R. BLUMENSCHEIN, M.D.; FRANK C. SCHELL, M.D.; AMAN U. BUZDAR, M.D.; MANUEL VALDIVIESO, M.D.; GERALD P. BODEY, M.D.
▸Requests for reprints should be addressed to Hwee-Yong Yap, M.D.; Medical Breast Service; M.D. Anderson Hospital and Tumor Institute; 6723 Bertner Avenue; Houston, TX 77030.
YAP H., BLUMENSCHEIN G., SCHELL F., BUZDAR A., VALDIVIESO M., BODEY G.; Dihydroxyanthracenedione: A Promising New Drug in the Treatment of Metastatic Breast Cancer. Ann Intern Med. 1981;95:694-697. doi: 10.7326/0003-4819-95-6-694
Download citation file:
Published: Ann Intern Med. 1981;95(6):694-697.
Thirty-one patients who had metastatic breast cancer extensively pretreated with combination chemotherapy, including doxorubicin, were treated with dihydroxyanthracenedione, 3 to 4 mg/m2 body surface are a daily for 5 consecutive days every 4 weeks. Of 27 evaluable patients, one achieved a complete response and five had partial responses. Furthermore, responses were seen in patients who were refractory to doxorubicin, indicating a lack of cross-resistance between doxorubicin and dihydroxyanthracenedione. Acute drug toxicity was insignificant except for severe granulocytopenia at the dose level of 4 mg/m2 · d. The median duration of remission had not been reached, but was more than 26 weeks, with four of the six responding patients still in remission at last follow-up. We believe that dihydroxyanthracenedione has significant activity against refractory metastatic breast cancer and further evaluation is warranted.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Hematology/Oncology, Neurology, Multiple Sclerosis, Breast Cancer.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only